|
|
|
|
|
by wdewind
3100 days ago
|
|
There is a wide difference in the prevalence, severity of condition and extremity of treatment in some of these conditions. Poor eyesight afflicts a large portion of the population, but the severity of the issue and the extremity of the treatment are not high. It doesn't impact your ability to maintain social relationships, for instance, and the treatment is very well understood and has low/no side effects. Color blindness, partial deafness etc., are readily and inexpensively treated, but they do not afflict 5-10% of the young and healthy population. The issue comes in when we start saying 5-10% of the population has an extreme condition (ie: impacts ability to maintain work, social relationships etc.) with a relatively severe (ie: fairly large % of users experiencing side effects) treatment necessary. When you put that in the context of our massively volatile understanding of mental illness over the last 50 years, as well as the massive incentives for pharmaceutical companies to push a specific narrative, it is difficult for me not to see a red flag. |
|
Isn't color blindness in men right in that range?